Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nitazoxanide

FDA-approved product (tablet, oral), marketed as Alinia, Nitazoxanide.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Nitazoxanide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Amebiasis
  • Diarrhea

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other agents against amoebiasis and other protozoal diseases
FDA pharmacologic class
Antiprotozoal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01AX11; FDA class Antiprotozoal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis77.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 1 of 1 lab record
Open Nitazoxanide in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nitazoxanide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Clinical Trial Evaluating Fecal Microbiota Transplantation (FMT) in Adolescents With ADHD

    NCT07756255 · start 2026-08-31

    Registered record
    Registry ID
    NCT07756255
    Conditions
    ADHD; ADHD - Attention Deficit Disorder With Hyperactivity; ADHD - Combined Type
    Interventions
    Fecal Microbiota Transplant (FMT); Nitazoxanide 500mg BID; Vancomycin 250mg BID; Placebo Vancomycin; Placebo Nitazoxanide; Pico-Salax; Placebo Fecal Microbiota Transplantation (FMT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-08-31
    Completion
    2029-08-31
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionADHD; ADHD - Attention Deficit Disorder With Hyperactivity; ADHD - Combined Type
    InterventionFecal Microbiota Transplant (FMT); Nitazoxanide 500mg BID; Vancomycin 250mg BID; Placebo Vancomycin +3 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness

    NCT05157243 · start 2024-08

    Registered record
    Registry ID
    NCT05157243
    Conditions
    COVID-19
    Interventions
    Nitazoxanide; Vitamin Super-B Complex; Placebo; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2024-08
    Completion
    2025-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionNitazoxanide; Vitamin Super-B Complex; Placebo; Standard of Care
    PhasePhase 3
    Registry statusWithdrawn

  • Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness

    NCT05157269 · start 2024-08

    Registered record
    Registry ID
    NCT05157269
    Conditions
    COVID-19
    Interventions
    Nitazoxanide; Placebo; Vitamin Super-B Complex
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2024-08
    Completion
    2025-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionNitazoxanide; Placebo; Vitamin Super-B Complex
    PhasePhase 3
    Registry statusWithdrawn

  • Nitazoxanide vs Metronidazole for Entamoeba Diarrhea in Children

    NCT07790926 · start 2024-04-02

    Registered record
    Registry ID
    NCT07790926
    Conditions
    Entamoeba Histolytica Diarrhea
    Interventions
    Nitazoxanide; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-04-02
    Completion
    2025-04-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEntamoeba Histolytica Diarrhea
    InterventionNitazoxanide; Metronidazole
    PhasePhase 2
    Registry statusCompleted

  • Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

    NCT05894954 · start 2023-07-31

    Registered record
    Registry ID
    NCT05894954
    Conditions
    Mild Cognitive Impairment; Dementia, Mild
    Interventions
    Precision Medicine Approach; Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises; Standard-of-Care; Lifestyle including diet, exercise, stress management
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-07-31
    Completion
    2026-02-09
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild Cognitive Impairment; Dementia, Mild
    InterventionPrecision Medicine Approach; Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises; Standard-of-Care; Lifestyle including diet, exercise, stress management
    PhasePhase 3
    Registry statusCompleted

  • Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis

    NCT05480878 · start 2022-12-02

    Registered record
    Registry ID
    NCT05480878
    Conditions
    Rheumatoid Arthritis
    Interventions
    Placebo; Nitazoxanide 500Mg Oral Tablet; Escitalopram 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-12-02
    Completion
    2023-04-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionPlacebo; Nitazoxanide 500Mg Oral Tablet; Escitalopram 10mg
    PhasePhase 3
    Registry statusCompleted

  • Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

    NCT05368935 · start 2022-04-25

    Registered record
    Registry ID
    NCT05368935
    Conditions
    Renal Impairment; Renal Disease; Kidney Disease
    Interventions
    Nitazoxanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-04-25
    Completion
    2022-09-09
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Impairment; Renal Disease; Kidney Disease
    InterventionNitazoxanide
    PhasePhase 1
    Registry statusCompleted

  • Interest of Nitazoxanide Treatment of Enterocytozoon Bieneusi Intestinal Microsporidiosis

    NCT05417815 · start 2022-04-01

    Registered record
    Registry ID
    NCT05417815
    Conditions
    Microsporidiosis Intestinal
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-04-01
    Completion
    2022-06-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMicrosporidiosis Intestinal
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

    NCT05041907 · start 2021-09-30

    Registered record
    Registry ID
    NCT05041907
    Conditions
    COVID-19
    Interventions
    Nirmatrelvir/ritonavir (e.g. PAXLOVID™); Nitazoxanide; Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™); Hydroxychloroquine; No treatment; Monoclonal antibodies; Fluoxetine; Molnupiravir; Sotrovimab; Ensitrelvir; Monoclonal antibodies; Favipiravir; Ivermectin; Remdesivir; Atilotrelvir/ritonavir; Metformin; Nirmatrelvir/ritonavir; Nirmatrelvir/ritonavir; Nirmatrelvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-09-30
    Completion
    2027-01
    Enrolment
    3,800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionNirmatrelvir/ritonavir (e.g. PAXLOVID™); Nitazoxanide; Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™); Hydroxychloroquine +15 more
    PhasePhase 2
    Registry statusRecruiting

  • Comparative Study of Secondary Prophylaxis for SBP

    NCT06827756 · start 2021-03-01

    Registered record
    Registry ID
    NCT06827756
    Conditions
    Spontaneous Bacterial Peritonitis; Cirrhoses, Liver; Ascites
    Interventions
    Norfloxacin 400 MG; Nitazoxanide 500 MG; Colistin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-03-01
    Completion
    2022-02-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis; Cirrhoses, Liver; Ascites
    InterventionNorfloxacin 400 MG; Nitazoxanide 500 MG; Colistin
    PhasePhase 4
    Registry statusCompleted

  • Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis

    NCT04746937 · start 2021-03

    Registered record
    Registry ID
    NCT04746937
    Conditions
    Spontaneous Bacterial Peritonitis
    Interventions
    Nitazoxanide; Norfloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-03
    Completion
    2022-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis
    InterventionNitazoxanide; Norfloxacin
    PhasePhase 3
    Registry statusUnknown

  • COVID-19 Prophylaxis South Africa (COVER HCW)

    NCT04561063 · start 2020-12-08

    Registered record
    Registry ID
    NCT04561063
    Conditions
    Covid19; SARS-CoV Infection
    Interventions
    Nitazoxanide; Sofosbuvir/Daclatasvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-12-08
    Completion
    2022-02-28
    Enrolment
    1,950

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; SARS-CoV Infection
    InterventionNitazoxanide; Sofosbuvir/Daclatasvir
    PhasePhase 2
    Registry statusCompleted

  • A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19

    NCT04605588 · start 2020-12-02

    Registered record
    Registry ID
    NCT04605588
    Conditions
    SARS-CoV Infection; Covid19
    Interventions
    Nitazoxanide; Placebo Nitazoxanide; Ribavirin; Placebo Ribavirin; Hydroxychloroquine; Placebo Hydroxychloroquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-12-02
    Completion
    2021-02-04
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSARS-CoV Infection; Covid19
    InterventionNitazoxanide; Placebo Nitazoxanide; Ribavirin; Placebo Ribavirin +2 more
    PhasePhase 2
    Registry statusTerminated

  • Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts

    NCT04788407 · start 2020-12-01

    Registered record
    Registry ID
    NCT04788407
    Conditions
    Covid19; SARS-CoV-2 Infection; Households Contacts
    Interventions
    Nitazoxanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-12-01
    Completion
    2022-04-30
    Enrolment
    456

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; SARS-CoV-2 Infection; Households Contacts
    InterventionNitazoxanide; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Catalysing the Containment of COVID-19

    NCT04523090 · start 2020-08-27

    Registered record
    Registry ID
    NCT04523090
    Conditions
    COVID-19
    Interventions
    Nitazoxanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2020-08-27
    Completion
    2022-08-12
    Enrolment
    322

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionNitazoxanide; Placebo
    PhasePhase 2 / Phase 3
    Registry statusTerminated